BetterLife Pharma Inc. filed its unaudited interim financial statements for the three and six months ended July 31, 2026, reporting a net loss of CAD 2.7 million. The company closed a public offering on September 17, 2026, raising gross proceeds of $138.7 million by issuing common shares and pre-funded warrants to fund Phase 1A through Phase 2 clinical trials for its BETR-001 drug candidate. Subsequent events include the repayment or conversion dispute regarding a CAD 2 million convertible debenture held by director Dr. Steven Sangha, and the exercise of warrants generating $659,000 in proceeds. BetterLife Pharma Inc. is an emerging biotechnology company focused on developing compounds for neurological pain and viral infections.
